Last month, we posted a lengthy article titled Screening Tests for Preeclampsia. On August 14, a press release from PerkinElmer announced the launch of its new screening test for early onset preeclampsia, Preeclampsia Screen™ | T1. This month we posed questions to PerkinElmer Labs/NTD. These are the answers we received to five of the questions, which are representative of the questions you asked us.

How much will the screening test cost?

The list price of the test is $495. This will be billed to a patient's insurance, if available. If the test is not covered by a patient's insurance and the patient takes advantage of applicable payment options, they can expect to spend approximately $200 out of pocket for the test.

Will my insurance cover it?

This is uncertain, at this time, as the screening test just launched on August 1, 2013. It is our plan to submit to insurances and work with them on reimbursement for these new claims.

Will it be available everywhere in the U.S., and can any doctor or midwife order it for me?

It must be ordered by a qualified health care provider who is able to order laboratory tests and who has set up an account with PerkinElmer Labs/NTD. It is available to all qualified healthcare providers in the country.

Is it available outside the US?

Yes. Samples can be received at PerkinElmer Labs/NTD from outside the U.S., as long as they conform to all sample and shipping requirements, including any international regulations.

Will the screening test tell me when I might start getting sick, if I'm going to get PE?

The test will not tell you or your healthcare provider when you may begin having symptoms of preeclampsia. What it can tell your healthcare provider is whether or not you are at increased risk of developing early onset preeclampsia, which is preeclampsia that results in the delivery of the fetus before 34 weeks gestation.

 
Hits: (176)

Professors Chris Redman and Isabel Walker, co-authors of Pre-eclampsia: The Facts (Oxford University Press 1992) and co-founders of Action on Pre-eclampsia (APEC) in the UK, are seeking input from members of the Preeclampsia Foundation for their latest book, The Pre-eclampsia Survival Guide.

The new book, also co-authored by Joyce Cowan, a midwife who is Director of New Zealand APEC (NZAPEC), will be a comprehensive guide to pre-eclampsia for women and midwives. It will cover everything from historical theories to current treatments; from causation to detection; from prevention to management. It will be rooted very firmly in the real experiences of women who have suffered pre-eclampsia - and that's where you come in.

The authors are keen to illustrate their key points with real life case histories gathered from several different parts of the world. You could be part of this process by contributing to an online survey. Your input will only be used for the book, not any other research studies.

The Pre-eclampsia Survival Guide is expected to be published in the spring/summer of 2013. We will be reviewing the book in draft form to ensure that North American management practices are represented, since the intended audience includes all English speakers worldwide and, of course, we will have the finished product available in our Marketplace.

Despite conflicts over the hyphen in "pre-eclampsia", our universal understanding and management of the hypertensive disorders of pregnancy is mostly aligned in high resource countries. As with most medical issues, there will always be a variety of opinions, especially in a disorder with the moniker "the disease of theories", but we expect this will be a very sought after and trusted reference book for patients and providers alike.

 

Hits: (152)

The Preeclampsia Registry

    The Preeclampsia Registry is a "Living Database" bringing together those affected, their family members, and researchers to advance knowledge and discover preventions and treatments for preeclampsia, HELLP syndrome, and related hypertensive disorders of pregnancy.

Research Resources

Research Funding Available

JOIN OUR MAILING LIST. We respect your privacy.